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Cerebrovascular Complications of COVID-19
Jeffrey M. Katz, MD; Richard B. Libman, MD; Jason J. Wang , PhD; Pina Sanelli, MD; Christopher G. Filippi, MD;
Michele Gribko , DNP; Steven V. Pacia, MD; Ruben I. Kuzniecky, MD; Souhel Najjar , MD; Salman Azhar, MD
BACKGROUND AND PURPOSE: Coronavirus disease 2019 (COVID-19) evolved quickly into a global pandemic with myriad systemic
complications, including stroke. We report the largest case series to date of cerebrovascular complications of COVID-19 and
compare with stroke patients without infection.
METHODS: Retrospective case series of COVID-19 patients with imaging-confirmed stroke, treated at 11 hospitals in New
York, between March 14 and April 26, 2020. Demographic, clinical, laboratory, imaging, and outcome data were collected,
and cases were compared with date-matched controls without COVID-19 from 1 year prior.
RESULTS: Eighty-six COVID-19–positive stroke cases were identified (mean age, 67.4 years; 44.2% women). Ischemic stroke
(83.7%) and nonfocal neurological presentations (67.4%) predominated, commonly involving multivascular distributions
(45.8%) with associated hemorrhage (20.8%). Compared with controls (n=499), COVID-19 was associated with in-hospital
stroke onset (47.7% versus 5.0%; P<0.001), mortality (29.1% versus 9.0%; P<0.001), and Black/multiracial race (58.1%
versus 36.9%; P=0.001). COVID-19 was the strongest independent risk factor for in-hospital stroke (odds ratio, 20.9 [95%
CI, 10.4–42.2]; P<0.001), whereas COVID-19, older age, and intracranial hemorrhage independently predicted mortality.
CONCLUSIONS: COVID-19 is an independent risk factor for stroke in hospitalized patients and mortality, and stroke presentations
are frequently atypical.
Key Words: cerebrovascular disorders ◼ demography ◼ odds ratio ◼ pandemics ◼ risk factors

I

n December 2019, coronavirus disease 2019 (COVID19)—the disease caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2)—first appeared
as a respiratory illness in Wuhan, China.1 Since then, it
has become a global pandemic, infecting at least 15.8
million people worldwide, including >4.1 million people in
the United States.2 SARS-CoV-2 infection has protean
presentations and clinical courses, ranging from asymptomatic carriers3 to critical illness with acute respiratory
distress syndrome and multiorgan failure secondary to
an accentuated immune response.4–6 Hypercoagulability
may also develop, resulting in venous and arterial thromboembolic disease, including stroke.7–12
To date, only 13 stroke patients from China,9 7 patients
from the United Kingdom,10 and 37 patients from the
United States11,12 have been described in the literature.

We present the largest series to date of COVID-19
patients who either presented with stroke or had cerebrovascular complications while hospitalized for COVID-19.

METHODS
This is a retrospective case series of COVID-19 patients concurrently diagnosed with stroke, admitted to 11 Northwell
Health hospitals in New York City and Long Island between
March 14 and April 26, 2020. Our institutional review board
approved this study as minimal risk, waiving informed consent.
The data supporting the findings of this study are available from
the corresponding author upon reasonable request.
Inclusion required (1) confirmed SARS-CoV-2 infection
by polymerase chain reaction testing of nasopharyngeal swab
samples and (2) concurrent stroke diagnosis, defined as stroke
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and angiographic findings were attained by independent neuroradiologist review.

COVID-19
SARS-CoV-2

STATISTICAL ANALYSIS

coronavirus disease 2019
severe acute respiratory syndrome
coronavirus 2

symptom onset during COVID-19 illness or onset of COVID19 symptoms or SARS-CoV-2 polymerase chain reaction
positivity within 14 days of stroke symptom onset. Only imaging-confirmed cases were included. Historical controls without
COVID-19 were comprised of all stroke patients admitted 1
year earlier, between the same dates, to the same hospitals.
Data obtained from retrospective chart review and Get
With The Guidelines-Stroke and COVID-19 databases
included demographic, clinical, laboratory, and outcome measures. Additional details may be found in Materials in the Data
Supplement. Clinical outcome was measured by discharge disposition, including death. Case neuroimaging data including
brain computed tomography or magnetic resonance imaging

A bivariate analysis of demographic, clinical, and outcome variables comparing COVID-19 stroke patients to
controls was performed using χ2. A logistic regression
model was created to determine independent risk factors for in-hospital stroke and mortality. Statistical significance was considered for P<0.05. All statistical analyses
were done in SAS v9.4 (SAS Institute).

RESULTS
In the study period, 10 596 COVID-19 patients were
hospitalized (mean [range] percent hospital admissions
with COVID-19, 43.3% [29.8%–64.2%]), and of these,
86 (0.8%; mean age [range], 67.4 [25–94] years; 44.2%

Figure. Coronavirus disease 2019 (COVID-19)–associated large vessel occlusion.
A, Angiogram displaying distal basilar artery occlusion (black arrow) in a 54-y-old man. B, Post-thrombectomy, magnetic resonance imaging
diffusion shows right inferior cerebellar and paramedian pontine infarctions. C, Computed tomography (CT) head showing bilateral middle cerebral
artery infarctions in a 62-y-old woman with. D, CT angiogram demonstrating occlusions of proximal left middle cerebral artery (white arrows) and
terminal right internal carotid artery and middle cerebral artery (black arrow).
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Table 1.

Fifty-eight patients (67.4%) presented with nonfocal
deficits. Encephalopathy was the most common presenting symptom (n=41), followed by seizures, generalized
weakness, falls, and dizziness. Many had substantial
COVID-19 complications while hospitalized, including
pneumonia (88.4%), hypoxia (69.8%), and end-organ
dysfunction (67.4%), with frequent critical-care admission (51.2%) and mechanical ventilation (44.0%). Of
45 patients testing positive for COVID-19 after stroke
onset, most had mild COVID-19 symptoms (n=23) or

Bivariate Analysis Comparing Stroke Patients With and Without COVID-19
COVID-19

Control

n=86

n=499

Category

n (%)

n (%)

P Value

Age, y

20–69

46 (53.5)

219 (43.9)

0.099

≥70

40 (46.5)

280 (56.1)

Sex

Female

38 (44.2)

234 (46.9)

0.642

Race

White

26 (30.2)

266 (53.3)

0.001

115 (23.1)

Variable
Demographic and clinical

Stroke subtype

Stroke onset location
Stroke risk factors

Black

27 (31.4)

Asian

10 (11.6)

49 (9.8)

Multiracial/other

23 (26.7)

69 (13.8)

Ischemic

72 (83.7)

397 (79.6)

Hemorrhagic

14 (16.3)

102 (20.4)

In hospital

41 (47.7)

25 (5.0)

Hypertension

63 (73.3)

369 (74.0)

0.893

Diabetes mellitus

179 (35.9)

35 (40.7)

0.391

Dyslipidemia

28 (32.6)

206 (41.3)

0.127

Smoking

6 (7.0)

45 (9.0)

0.535

Atrial fibrillation

63 (12.6)

8 (9.3)

0.384
0.008

Past stroke or TIA

Obesity
Admission medication

<0.001

9 (10.5)

115 (23.1)

None

15 (17.4)

66 (13.2)

0.296

BMI ≥30 kg/m2

27 (31.4)

136 (27.3)

0.429

Antithrombotic

27 (31.4)

246 (49.3)

0.002

Antihypertensive

48 (55.8)

334 (66.9)

0.045

Lipid lowering

36 (41.9)

233 (46.7)

0.406

Deep vein thrombosis
Acute treatment

0.371

<0.001

13 (15.1)

24 (4.8)

Intravenous r-tPA

7 (8.1)

71 (14.2)

0.125

Thrombectomy

1 (1.2)

23 (4.6)

0.137

Vital signs and blood work
≥140 mm Hg

43 (50.0)

341 (68.3)

0.001

Heart rate

≥100 bpm

34 (39.5)

70 (14.0)

<0.001

Platelets

<150 K/uL

19 (22.1)

55 (11.0)

0.004

≥1.2

36 (41.9)

94 (18.8)

<0.001

Home

25 (29.1)

228 (45.7)

<0.001

Rehabilitation

31 (36.1)

210 (42.1)

Expired/hospice

30 (34.9)

61 (12.2)

25 (29.1)

45 (9.0)

Systolic blood pressure

INR
Outcome
Hospital discharge disposition

Mortality

<0.001

BMI indicates body mass index; COVID-19, coronavirus disease 2019; INR, international normalized ratio; r-tPA, recombinant tissuetype plasminogen activator; and TIA, transient ischemic attack.
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women) met inclusion with imaging-confirmed infarctions
(83.7%) or exclusive intracranial hemorrhage (16.3%). In
the ischemic subgroup, 20.8% had associated brain hemorrhage, including hemorrhagic transformation (n=6) and
simultaneous hemorrhage and infarction (n=9). Multivascular territory infarction (45.8%) was most common. Of
ischemic patients with noninvasive angiography (38.9%),
57.1% had extracranial or intracranial large vessel occlusion (Figure).
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were asymptomatic (n=13). Stroke onset during hospitalization for COVID-19 occurred in 41 patients (47.7%).
The majority of these were diagnosed by brain imaging
for encephalopathy (n=23), while only 9 had suddenonset focal deficits.
Table 1 compares demographic, clinical, laboratory,
and outcome variables of COVID-19 stroke patients and
controls (n=499). No significant differences were found
in terms of age or sex. Black and multiracial minorities
were significantly more common in the COVID-19 cohort
(58.1% versus 36.9%; P=0.001). COVID-19 patients
were significantly more likely to have stroke while hospitalized (47.7% versus 5.0%; P<0.001) and had significantly less frequent cerebrovascular history (10.5%
versus 23.1%; P=0.008) and preadmission antithrombotic and antihypertensive use. More frequent admission
tachycardia, thrombocytopenia, international normalized
ratio elevation, and deep vein thrombosis were observed
in COVID-19 patients. COVID-19 patients were significantly more likely to die (P<0.001), with 29.1% all-cause
mortality.
Multivariable logistic regression results are presented
in Table 2. COVID-19 was the strongest independent
predictor of stroke in hospitalized patients. Other risk
factors included male sex and deep vein thrombosis. Cerebrovascular history predicted decreased inhospital stroke risk. COVID-19, age ≥70 years, atrial
fibrillation, and any intracranial hemorrhage, including
hemorrhagic transformation, were independent risk factors for mortality.

absence of cerebrovascular history and evidence of
coagulopathy specific to COVID-19 stroke patients. This
high in-hospital stroke rate was found by others12 and
may reflect the acuity of COVID-19 patients hospitalized
during the pandemic peak.
A significant racial disparity was noted with Black
and multiracial minorities being the majority (58%) of
the COVID-19 stroke cohort. In a consecutive series of
5700 COVID-19 patients hospitalized in the same system, 52% were Black/multiracial.4 Therefore, this overrepresentation may result from the higher prevalence of
COVID-19 in these populations. Inequalities in risk factor
modification, healthcare access, socioeconomics, diet,
and genetic predilections may also contribute.
The majority of COVID-19 patients presented with
nonfocal deficits (67.4%), predominantly encephalopathy, ranging from confusion to coma. In previous studies,
stroke chameleons accounted for up to 22% of stroke
patients, and altered mental status is the most common
admitting diagnosis.13 COVID-19 patients were also more
likely to die, with 29% in-hospital mortality. Although not
directly comparable given the methodological differences
between studies, this rate is higher than the 21% COVID19 mortality rate separately reported by our health system.4 COVID-19 was the strongest independent risk
factor for mortality. While we were unable to differentiate
stroke-specific mortality from the independent lethality of
COVID-19, our excess mortality reflects an even worse
prognosis for COVID-19–associated stroke.
Our study has several strengths and limitations.
Numerous factors likely resulted in undercounting the
COVID-19 stroke population. While inclusion of only
patients with imaging-confirmed stroke is a strength,
many potential stroke patients with normal initial brain
imaging did not undergo repeat imaging and were not
included. In addition, SARS-CoV-2 polymerase chain
reaction–negative stroke patients with other biomarkers suggesting infection were excluded. Given the false
negative rate of COVID-19 testing,14 the true burden of

DISCUSSION
A major finding of our study was the frequency of inhospital stroke onset, accounting for 48% of the COVID19 cohort compared with 5% of controls. As COVID-19
was the strongest independent predictor of in-hospital
stroke onset, a causal association between COVID-19
and stroke is suggested and further supported by the
Table 2.

Independent Risk Factors for In-Hospital Stroke and Mortality
In-Hospital Stroke

Parameter

Odds Ratio (95% CI)

COVID-19

20.9 (10.4–42.0)

Mortality
Odds Ratio (95% CI)

P Value

<0.001

P Value

3.3 (1.8–6.1)

<0.001

Age ≥70 y

1.2 (0.6–2.4)

0.557

2.4 (1.3–4.5)

0.007

Sex, male

2.2 (1.1–4.3)

0.028

1.2 (0.7–2.2)

0.456

Black race

0.6 (0.3–1.6)

0.333

0.6 (0.3–1.4)

0.276

ICH

0.8 (0.4–1.8)

0.637

2.1 (1.2–3.8)

0.013

DVT

5.4 (2.0–14.5)

0.001

1.7 (0.7–4.3)

0.240

Atrial fibrillation

0.3 (0.1–1.1)

0.075

2.4 (1.1–5.5)

0.038

Obesity

1.8 (0.9–3.6)

0.096

0.7 (0.4–1.5)

0.379

Past stroke or transient ischemic attack

0.3 (0.1–0.8)

0.026

0.5 (0.2–1.2)

0.101

ICH includes hemorrhagic transformation. COVID-19 indicates coronavirus disease 2019; DVT, deep vein thrombosis; and ICH,
intracranial hemorrhage.
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COVID-19–related cerebrovascular complications may
be underestimated. Nevertheless, our overall COVID-19
stroke rate of 0.8% is similar to the 0.9% rate reported by
others.12 By including historical controls, we were able to
demonstrate that COVID-19 is an independent risk factor
for stroke, specifically in-hospital onset, and avoided contaminating our control group with false negative COVID19 patients (see the Data Supplement for details). Yet, by
not including a contemporaneous comparison group, we
were unable to control for differences in health access
and hospital staffing during the pandemic. To our knowledge, ours is the largest series to date of COVID-19
stroke patients and includes outcome for all patients.
In conclusion, COVID-19 is a strong independent risk
factor for stroke in hospitalized patients, and stroke in
COVID-19 portends increased mortality. COVID-19–related stroke is more frequent among racial minorities, and
presentations are often atypical, without focal deficits, in
multivascular territories, and with concomitant hemorrhages. Recognition is, therefore, critical, since prompt
diagnosis may impact management.
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